These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24102472)

  • 21. The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
    Patel AA; Ogden K; Mody SH; Bookhart B
    J Med Econ; 2015 May; 18(5):323-32. PubMed ID: 25557176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
    Akwaa F; Spyropoulos AC
    Curr Med Res Opin; 2014 Nov; 30(11):2179-90. PubMed ID: 25105309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current status of the management of venous thromboembolism in Japan].
    Nakamura M
    Nihon Rinsho; 2014 Jul; 72(7):1298-302. PubMed ID: 25163325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylaxis against venous thromboembolism in orthopedic surgery.
    Liu LT; Ma BT
    Chin J Traumatol; 2006 Aug; 9(4):249-56. PubMed ID: 16849000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal function and venous thromboembolic diseases.
    Janus N; Mahé I; Launay-Vacher V; Laroche JP; Deray G
    J Mal Vasc; 2016 Dec; 41(6):389-395. PubMed ID: 28029509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of apixaban vs low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism.
    Browne C; Lanitis T; Hamilton M; Li X; Horbyluk R; Mardekian J; Kongnakorn T; Cohen A
    J Med Econ; 2017 Jan; 20(1):98-106. PubMed ID: 27822962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate.
    Ageno W; Casella IB; Han CK; Raskob GE; Schellong S; Schulman S; Singer DE; Kimura K; Tang W; Desch M; Goldhaber SZ
    Thromb Haemost; 2017 Jan; 117(2):415-421. PubMed ID: 27853808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [From apixaban to aspirin in the prevention of recurrent venous thromboembolism].
    Diez-Ewald M
    Invest Clin; 2013 Sep; 54(3):231-3. PubMed ID: 24354237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis.
    Schurgers LJ; Spronk HM
    Thromb Haemost; 2014 Nov; 112(5):909-17. PubMed ID: 25298033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of the Target-Specific Oral Anticoagulants in Development for the Treatment and Prevention of Venous Thromboembolism.
    Devabhakthuni S; Yoon CH; Pincus KJ
    J Pharm Pract; 2016 Aug; 29(4):392-405. PubMed ID: 25634013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current management of venous thromboembolism in Japan: Current epidemiology and advances in anticoagulant therapy.
    Nakamura M; Yamada N; Ito M
    J Cardiol; 2015 Dec; 66(6):451-9. PubMed ID: 25896176
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic Therapies in Anticoagulation.
    Ferreira JL; Wipf JE
    Med Clin North Am; 2016 Jul; 100(4):695-718. PubMed ID: 27235611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
    Lu X; Lin J
    BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New anticoagulants for the treatment of venous thromboembolism.
    Fernandes CJ; Alves Júnior JL; Gavilanes F; Prada LF; Morinaga LK; Souza R
    J Bras Pneumol; 2016 Apr; 42(2):146-54. PubMed ID: 27167437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of venous thromboembolism.
    Wells PS; Forgie MA; Rodger MA
    JAMA; 2014 Feb; 311(7):717-28. PubMed ID: 24549552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamics, pharmacokinetics and clinical efficacy of apixaban in the treatment of thrombosis.
    Zheng SS; Chong JJ; Chong BH
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):575-80. PubMed ID: 26982962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guideline update. VTE disease: which agents, and when.
    Holten KB; Merok J
    J Fam Pract; 2009 Mar; 58(3):E1. PubMed ID: 19284934
    [No Abstract]   [Full Text] [Related]  

  • 38. Treating patients with cancer and acute venous thromboembolism.
    Donadini MP; Squizzato A; Ageno W
    Expert Opin Pharmacother; 2016; 17(4):535-43. PubMed ID: 26606049
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial.
    Liem TK; Deloughery TG
    Semin Vasc Surg; 2011 Sep; 24(3):157-61. PubMed ID: 22153026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viscoelastic properties of plasma fibrin clots are similar in patients on rivaroxaban and vitamin K antagonists.
    Kopytek M; Zabczyk M; Natorska J; Siudut J; Malinowski KP; Ptaszek P; Glajcar A; Goralczyk T; Undas A
    J Physiol Pharmacol; 2019 Feb; 70(1):. PubMed ID: 31019123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.